SC
GSK icon

Savant Capital’s GSK GSK Stock Holding History

Savant Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.55M Buy
68,581
+52,408
+324% +$2.77M 0.01% 480
2026
Q1 		$893K Buy
16,173
+4,256
+36% +$231K ﹤0.01% 668
2025
Q4 		$584K Buy
11,917
+2,887
+32% +$135K ﹤0.01% 772
2025
Q3 		$390K Sell
9,030
-697
-7% -$27.2K ﹤0.01% 901
2025
Q2 		$374K Buy
9,727
+2,444
+34% +$93.4K ﹤0.01% 867
2025
Q1 		$282K Sell
7,283
-843
-10% -$30.9K ﹤0.01% 866
2024
Q4 		$275K Buy
8,126
+2,504
+45% +$90.1K ﹤0.01% 1153
2024
Q3 		$230K Buy
+5,622
New +$230K ﹤0.01% 1218
2024
Q2 		– Sell
-8,871
Closed -$380K – 1296
2024
Q1 		$380K Buy
8,871
+537
+6% +$22.1K ﹤0.01% 813
2023
Q4 		$309K Sell
8,334
-2,606
-24% -$93.6K ﹤0.01% 695
2023
Q3 		$397K Sell
10,940
-78
-0.7% -$2.77K 0.01% 580
2023
Q2 		$393K Buy
11,018
+1,822
+20% +$65.4K 0.01% 572
2023
Q1 		$327K Buy
9,196
+712
+8% +$24.9K 0.01% 577
2022
Q4 		$227K Buy
+8,484
New +$283K 0.01% 532

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Savant Capital's GSK Position: Q2 2026 in Review

Savant Capital increased its GSK (GSK) stake by 324% in Q2 2026, buying an estimated $2.77M and bringing the position to 68,581 shares worth $3.55M. The position accounts for 0.01% of the portfolio, ranked #480.

Savant Capital first reported a position in GSK in Q4 2022 and has held it in 14 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Savant Capital held 68,581 shares of GSK worth $3.55M as of Q2 2026.
  • Savant Capital bought 52,408 GSK shares in Q2 2026, an estimated $2.77M.
  • GSK made up 0.01% of Savant Capital's portfolio in Q2 2026, its #480 holding.
  • Savant Capital first reported a position in GSK in Q4 2022 and has held it in 14 quarters since.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.